ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,065.60
      -0.08%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.67%
      Bitcoin
      67,080.76
      0.00%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Kura Oncology Inc (KURA)

      7. Kura Oncology Inc (KURA) News

      KURA

      Kura Oncology (KURA)

      Kura Oncology Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:KURA
      DateTimeSourceHeadlineSymbolCompany
      3:00PMiHub NewswireFeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements
      05/14/20247:30AMGlobeNewswire Inc.Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
      05/08/20247:30AMGlobeNewswire Inc.Kura Oncology to Participate in Bank of America Securities Healthcare ConferenceNASDAQ:KURAKura Oncology Inc
      05/03/20247:30AMGlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
      05/02/20244:05PMGlobeNewswire Inc.Kura Oncology Reports First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
      04/25/20247:30AMGlobeNewswire Inc.Kura Oncology to Report First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
      04/22/20247:30AMGlobeNewswire Inc.Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
      04/10/20247:30AMGlobeNewswire Inc.Kura Oncology to Participate in Stifel Targeted Oncology ForumNASDAQ:KURAKura Oncology Inc
      04/05/20247:30AMGlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
      03/06/20247:30AMGlobeNewswire Inc.Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaNASDAQ:KURAKura Oncology Inc
      03/01/20245:00PMGlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
      02/27/20244:52PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KURAKura Oncology Inc
      02/27/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
      02/27/20244:01PMGlobeNewswire Inc.Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
      02/26/20247:30AMGlobeNewswire Inc.Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid LeukemiaNASDAQ:KURAKura Oncology Inc
      02/22/20247:30AMGlobeNewswire Inc.Kura Oncology to Participate in Three Upcoming Investor ConferencesNASDAQ:KURAKura Oncology Inc
      02/20/20247:30AMGlobeNewswire Inc.Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
      02/15/20244:01PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KURAKura Oncology Inc
      02/15/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KURAKura Oncology Inc
      02/14/20245:58PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KURAKura Oncology Inc
      02/13/20245:23PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KURAKura Oncology Inc
      02/09/20245:21PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KURAKura Oncology Inc
      02/02/20247:30AMGlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
      01/31/20245:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
      01/31/20245:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
      01/31/20245:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
      01/31/20245:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
      01/30/20244:10PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
      01/30/20247:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
      01/30/20247:00AMGlobeNewswire Inc.Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid LeukemiaNASDAQ:KURAKura Oncology Inc
       Showing the most relevant articles for your search:NASDAQ:KURA